About: Pharmacokinetic Profile of Oral Administration of Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (FIP)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacokinetic Profile of Oral Administration of Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (FIP) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Pharmacokinetic Profile of Oral Administration of Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (FIP)
Creator	Norris, Jacqueline Yu, Jane Govendir, Merran Kimble, Benjamin
source	Medline; PMC
abstract	SIMPLE SUMMARY: In searching for antiviral agents against feline coronaviruses and feline caliciviruses, mefloquine, a human anti-malarial drug, has been demonstrated to reduce viral load of feline coronaviruses and feline calicivirus in infected cells. In this study, mefloquine was administered orally to seven clinically healthy cats twice weekly for four doses and mefloquine concentrations in blood were measured to investigate the pharmacokinetic profile—the movement of drug in the body. The maximum blood concentration of mefloquine was 2.71 ug/mL and was reached 15 h after a single oral dose was administered. Mefloquine side effects included vomiting following administration without food in some cats, and mild increases in symmetric dimethylarginine (SDMA), an early kidney biomarker. This study provides valuable information on mefloquine’s profile in cats as an introductory step towards investigating it as a potential treatment for feline coronavirus and feline calicivirus infection in cats. ABSTRACT: The pharmacokinetic profile of mefloquine was investigated as a preliminary study towards a potential treatment for feline coronavirus infections (such as feline infectious peritonitis) or feline calicivirus infections. Mefloquine was administered at 62.5 mg orally to seven clinically healthy cats twice weekly for four doses and mefloquine plasma concentrations over 336 h were measured using high pressure liquid chromatography (HPLC). The peak plasma concentration (Cmax) after a single oral dose of mefloquine was 2.71 ug/mL and time to reach Cmax (Tmax) was 15 h. The elimination half-life was 224 h. The plasma concentration reached a higher level at 4.06 ug/mL when mefloquine was administered with food. Adverse effects of dosing included vomiting following administration without food in some cats. Mild increases in serum symmetric dimethylarginine (SDMA), but not creatinine, concentrations were observed. Mefloquine may provide a safe effective treatment for feline coronavirus and feline calicivirus infections in cats.
has issue date	2020-06-08(xsd:dateTime)
bibo:doi	10.3390/ani10061000
bibo:pmid	32521771
has license	cc-by
sha1sum (hex)	4f9b315343dc1b1e93d2f5cda566a20812fbc66f
schema:url	https://doi.org/10.3390/ani10061000
resource representing a document's title	Pharmacokinetic Profile of Oral Administration of Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (FIP)
has PubMed Central identifier	PMC7341284
has PubMed identifier	32521771
schema:publication	Animals (Basel)
resource representing a document's body	covid:4f9b315343dc1b1e93d2f5cda566a20812fbc66f#body_text
is schema:about of	named entity 'Simple' named entity 'mild' named entity 'orally' named entity 'weekly' named entity 'Summary' named entity 'FIP' named entity 'Normal' named entity 'mefloquine' named entity 'vomiting' named entity 'study' named entity 'cells' named entity 'biomarker' named entity 'antiviral agents' named entity 'biomarker' named entity 'coronaviruses' named entity 'FIP' named entity 'Mefloquine' named entity '220 nm' named entity 'mode of action' named entity 'anaesthetised' named entity 'infection' named entity 'FIP' named entity 'feline calicivirus' named entity '13.0' named entity 'antiviral' named entity 'Japan' named entity 'Serum' named entity 'anti-malarial' named entity 'bile acid' named entity 'FIP' named entity 'gastrointestinal tract' named entity 'enterohepatic circulation' named entity 'Haematology' named entity 'blood glucose' named entity 'mefloquine' named entity 'mefloquine' named entity 'mefloquine' named entity 'plasma protein binding' named entity 'blood collection' named entity 'FIP' named entity 'vomiting' named entity 'mefloquine' named entity 'apparent volume of distribution' named entity 'pangolin' named entity 'mefloquine' named entity 'pharmacokinetic' named entity 'IFN-ω' named entity 'plasma' named entity 'Creatinine' named entity 'biochemical' named entity 'mefloquine' named entity 'serum' named entity '4.06' named entity 'gastrointestinal dysfunction' named entity 'SDMA' named entity 'animal research' named entity 'mefloquine' named entity 'mefloquine' named entity 'acetonitrile' named entity 'pharmacokinetic profile' named entity 'dengue virus' named entity 'mefloquine' named entity 'diarrhoea' named entity 'FCoV' named entity 'animal research' named entity 'blood collection' named entity 'resistance development' named entity 'coronavirus' named entity 'FIPV' named entity 'mefloquine' named entity 'Roche' named entity 'malaria' named entity 'mefloquine' named entity 'clinical signs' named entity 'mechanisms of actions' named entity 'clinical trial' named entity 'mefloquine' named entity 'pharmacokinetic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software